GEPT extract reduces Aβ deposition by regulating the Balance between production And Degradation of Aβ in APPV717I Transgenic Mice

Current Alzheimer Research

Volumn 6, Issue 2, 2009, Pages 118-131

  Tian, Jinzhou ^a,b,c,f   Shi, Jing ^a   Zhang, Leiming ^a   Yin, Junxiang ^a   Hu, Quan ^a   Xu, Yi ^a   Sheng, Shuli ^d   Wang, Pengwen ^a   Ren, Ying ^a   Wang, Rong ^d   Wang, Yongyan ^e  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b HUBEI UNIVERSITY OF CHINESE MEDICINE   (China)

^c BEIJING NORMAL UNIVERSITY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^f University of Chinese Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BETA ACTIN; BETA SECRETASE; DONEPEZIL; DRUG VEHICLE; GAMMA SECRETASE; GEPT EXTRACT; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE; PLANT EXTRACT; TAU PROTEIN; UNCLASSIFIED DRUG;

AMYLOIDOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CURCUMA LONGA; DRUG MEGADOSE; EPIMEDIUM; GENE OVEREXPRESSION; GINSENG; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MALE; MEDICINAL PLANT; MOUSE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TRANSGENIC MOUSE; TRANSGENIC MOUSE APPV717I; WESTERN BLOTTING;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANALYSIS OF VARIANCE; ANIMALS; ASPARTIC ENDOPEPTIDASES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; DRUGS, CHINESE HERBAL; GINSENOSIDES; HIPPOCAMPUS; HUMANS; INDANS; INSULYSIN; MALE; MEMORY; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; NEPRILYSIN; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; PRESENILIN-1; SPACE PERCEPTION; TIME FACTORS;

EID: 64549087197     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720509787602942     Document Type: Article

References (47)

1. Selkoe DJ. Normal and abnormal biology of the beta-amyloid precursor protein. Ann Rev Neurosci 17:489-517 (1994).
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease:progress and problems on the road to therapeutics. Science 297(5580):353-6 (2002).
3. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 39:10831-9 (2000).
4. El-Amouri SS, Zhu H, Yu J, Gage FH, Verma IM, Kindy MS. Neprilysin protects neurons against Abeta peptide toxicity. Brain Res. 1152:191-200 (2007).
5. Selkoe DJ. Alzheimer Disease:mechanistic understanding predicts novel therapies. Ann Intern Med 140:627-638 (2004).
6. Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, et al. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci USA, 101:3632-3637 (2004).
7. Dewachter I, Reverse D, Caluwaerts N, Ris L, Kuiperi C, Van den Haute C, et al. Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice. J Neurosci 22:3445-53 (2002).
8. Yin YI, Bassit B, Zhu L, Yang X, Wang C, Li YM. γ-Secretase Substrate Concentration Modulates the Aβ42/Aβ40 Ratio:Implications for Alzheimer's disease. J Biol Chem 282:23639-23644 (2007)
9. Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK, et al. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 290:150-3 (2000).
10. Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, et al. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat. Neurosci 4:233-4 (2001).
11. Wang DS, Dickson DW, Malter JS. beta-Amyloid Degradation and Alzheimer's Disease. J Biomed Biotechnol. 2006 (3):58406 (2006).
12. Farris W, Schiitz SG, Cirrito JR, Shankar GM, Sun X, George A, et al. Loss of Neprilysin Function Promotes Amyloid Plaque Formation and Causes Cerebral Amyloid Angiopathy. Am J Pathol. 171(1):241-51 (2007).
13. El-Amouri SS, Zhu H, Yu J, Gage FH, Verma IM, Kindy MS. Neprilysin protects neurons against Abeta peptide toxicity. Brain Res. 1152:191-200 (2007).
14. Vepsalainen S, Parkinson M, Helisalmi S, Mannermaa A, Soininen H, Tanzi R, et al. Insulin degrading enzyme is genetically associated with Alzheimer's disease in the Finnish population. J Med Genet. 44:606-8 (2007).
15. Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, et al. Enhanced proteolysis of β-Amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40:1087-1093 (2003).
16. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kok-men E. Mild cognitive impairment:clinical characterization and outcome. Arch Neurol 56:303-8 (1999).
17. Morris JC, Storandt M, McKeel DW Jr, Rubin EH, Price JL, Grant EA, et al. Cerebral amyloid deposition and diffuse plaques in "normal" aging:Evidence for presymptomatic and very mild Alzheimer's disease. Neurology 46:707-19 (1996).
18. Tian J, Zhu AH, Zhong J, Shi J. Wang YY. The effectiveness of GETO in the treatment of mild cognitive impairment in community elderly. Alzheimers Dement 1(2):S65 (2005).
19. Tian JZ, Zhu AH, Zhong J. A follow-up study on a randomized, single-blind control of GETO pills in treatment of memory disorder in elderly people with MCI in a Beijing community. [Article in Chinese] Zhongguo Zhong Yao Za Zhi 28:987-91 (2003).
20. Tian J, Xu Y, Sheng SL, Shi J, Yin JX and Wang YY. Influence of GETO extract on myelin sheath structure and myelin basic protein content in the brain with AD model. Alzheimers Dement 2 (3):S601 (2006).
21. Jeong YH, Park CH, Yoo J, Shin KY, Ahn SM, Kim HS, et al. Chronic stress accelerates learning and memory impairments and increases amyloid deposition in APPV717I-CT100 transgenic mice, an Alzheimer's disease model. FASEB J. 20(6):729-31 (2006).
22. Lambourne SL, Sellers LA, Bush TG, Choudhury SK., Emson PC, Suh YH, et al. Increased tau phosphorylation on mitogen-activated protein kinase consensus sites and cognitive decline in transgenic models for Alzheimer's disease and FTDP-17:evidence for distinct molecular processes underlying tau abnormalities. Mol Cell Biol 25:278-293 (2005).
23. Minkeviciene R, Banerjee P, Tanila H. Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease. J Pharmacol Exp Ther. 311:677-82 (2004).
24. Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A, et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 274:6483-92 (1999).
25. Mantle D, Pickering AT, Perry E. Medical Plant extracts for treatment of dementia. A review of their pharmacology, efficacy and tolerability. CNS Drugs 13:201-13 (2000).
26. Koldamova RP, Lefterov IM, Staufenbiel M, Wolfe D, Huang S, Glorioso JC, et al. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease, J Biol Chem 280:4079-4088 (2005).
27. Ognibene E, Middei S, Daniele S, Adriani W, Ghirardi O, Caprioli A, et al. Aspects of spatial memory and behavioral disinhibition in Tg2576 transgenic mice as a model of Alzheimer's disease. Behav Brain Res 156:225-232 (2005).
28. Walsh DM, Townsend M, Podlisny MB, Shankar GM, Fadeeva JV, Agnaf OE, et al. Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation, J Neurosci 25:2455-2462 (2005).
29. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DJ. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease, Proc. Natl. Acad. Sci. USA 98:8850-8855 (2001).
30. Gelinas DS, DaSilva K, Fenili D, St George-Hyslop P, McLaurin J. Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci USA 101 (Suppl 2) 14657-14662 (2004).
31. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphos-phorylated tau aggregates via the proteasome. Neuron 43:321-332 (2004).
32. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94:13287-92 (1997).
33. Dewachter I, van Dorpe J, Smeijers L, Gilis M, Kuiperi C, Laenen I, et al. Aging increased amyloid peptide and caused amyloid plaques in brain of old APP/V717I transgenic mice by a different mechanism than mutant presenilin1. J Neurosci 20:6452-8 (2000).
34. Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, et al. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci. USA 94:1550-5 (1997).
35. Xing Y, Zhang L, Li L. Effect of Shen-wu capsule on learning and memory ability and brain p-amyloid content in APP transgenic mice. Chin J Rehabil Theory Pract 11:324-6 (2005).
36. Hass C and De Strooper B. The presenilins in Alzheimer's diease proteolysis holds the key. Science 286:916-919 (1999).
37. Yu G, Nishimura M, Arawaka S, Levitan D, Zhang L, Tandon A, et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature 407:48-54 (2000).
38. Esler WP, Wolfe MS. A portrait of Alzheimer secretases:new features and familiar faces. Science 293:1449-1454 (2001).
39. Wang Y, Greig NH, Yu QS, Mattson MP. Presenilin-1 mutation impairs cholinergic modulation of synaptic plasticity and suppresses NMDA currents in hippocampus slices. Neurobiol Aging; [Epub ahead of print] (2008).
40. Zhang L, Xing Y, Ye CF, Ai HX, Wei HF, Li L. Learning-memory deficit with aging in APP transgenic mice of Alzheimer's disease and intervention by using tetrahydroxystilbene glucoside. Behav. Brain Res 173:246-254 (2006)
41. Selkoe, DJ. Clearing the brain's amyloid cobwebs. Neuron 32, 177180 (2001).
42. Eckman CB, Hersh LB, Thiele DL. Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc. Natl. Acad. Sci. USA 100, 6221-6226 (2003).
43. Farris W, Selkoe DJ. Kinetics of amyloid beta-protein degradation determined by novel fluorescence-and fluorescence polarization-based assays. J. Biol. Chem 278, 37314-37320 (2003).
44. Chen F, Eckman EA, Eckman CB. Reductions in levels of the Alzheimer's amyloid beta peptide after oral administration of ginse-nosides. FASEB J. 20:1269-71 (2006).
45. Tohda C, Matsumoto N, Zou K, Meselhy MR, Komatsu K. Abeta(25-35)-induced memory impairment, axonal atrophy, and synaptic loss are ameliorated by M1, A metabolite of proto-panaxadiol-type saponins. Neuropsychpharmacology 29:860-8(2004).
46. Wang Z, Zhang X, Wang H, Qi L, Lou Y. Neuroprotective effects of icaritin against beta amyloid-induced neurotoxicity in primary cultured rat neuronal cells via estrogen-dependent pathway. Neuro-science 145:911-22 (2007).
47. Jia H, Jiang Y, Ruan Y, Zhang Y, Ma X, Zhang J, et al. Tenuigenin treatment decreases secretion of the Alzheimer's disease amyloid beta-protein in cultured cells. Neurosci Lett. 367:123-8 (2004).